 WALTHAM, Mass., Sept. 20, 2021 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies, today announced that it has commenced an underwritten public offering of shares of its common stock and series B preferred stock the Series B Preferred. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian has granted the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B Preferred will be convertible into 66.67 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series B Preferred. 